Clinicopathologic significance of immunostaining of α-thalassemia/mental retardation syndrome X-linked protein and death domain–associated protein in neuroendocrine tumors
Authors:
- 16 August 2013
- journal article
- Published by Elsevier in Human Pathology
- Vol. 44 (10) , 2199-2203
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- PDX-1, CDX-2, TTF-1, and CK7American Journal of Surgical Pathology, 2012
- DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine TumorsScience, 2011
- mTOR expression and activity patterns in gastroenteropancreatic neuroendocrine tumoursEndocrine-Related Cancer, 2010
- Epidemiological study of gastroenteropancreatic neuroendocrine tumors in JapanJournal of Gastroenterology, 2010
- Neuroendocrine tumor epidemiologyCancer, 2008
- A Novel Transcription Regulatory Complex Containing Death Domain-associated Protein and the ATR-X Syndrome ProteinJournal of Biological Chemistry, 2004
- The ATRX syndrome protein forms a chromatin-remodeling complex with Daxx and localizes in promyelocytic leukemia nuclear bodiesProceedings of the National Academy of Sciences, 2003
- A 5‐decade analysis of 13,715 carcinoid tumorsCancer, 2003
- ATRX encodes a novel member of the SNF2 family of proteins: mutations point to a common mechanism underlying the ATR-X syndromeHuman Molecular Genetics, 1996
- Mutations in a putative global transcriptional regulator cause X-linked mental retardation with α-thalassemia (ATR-X syndrome)Cell, 1995